Novian Health

  • About Us
    • Overview
    • Management
    • Board Of Directors
    • Investors
  • Research & Products
    • Novilase® Breast Therapy
    • Clinical Trials & Registries
    • Publications
    • Intellectual Property
  • News
    • News & Press Releases
    • Media Coverage
    • Upcoming Events
  • Contact
    • Careers

New Device Offers Micro-Invasive Alternative to Lumpectomy for Benign Breast Tumors

June 26, 2007 by Novian Health

NEW DEVICE OFFERS MICRO-INVASIVE ALTERNATIVE TO LUMPECTOMY FOR BENIGN BREAST TUMORS

NOVIAN HealthTM Announces FDA Clearance for Patented Interstitial Laser Therapy

CHICAGO — June 26, 2007 – NOVIAN Health Inc. has developed an Interstitial Laser Therapy (ILT) device. In its initial application, the device, used to treat fibroadenomas (benign tumors) of the breast with tumor sizes up to 20 mm, was granted clearance from the U.S. Food and Drug Administration on May 2, 2007.

“We are extremely pleased to have received FDA clearance,” said Chip Appelbaum, President and CEO of NOVIAN Health. “This allows us to begin the commercialization phase of establishing and operating treatment sites, which will offer women an alternative to traditional surgery, as well as to expand our clinical development efforts in malignant tumors.” Previously known as Kelsey Inc., the company is now introducing NOVIAN Health as its new name, a reflection of the company’s mission in creating a new path in healthcare.

Lasers have been used successfully to ablate tissue in other areas of medicine, such as prostate cancer. The NOVIAN Health device applies this proven technology to treating non-malignant breast tumors. ILT is a micro-invasive technique that uses needle probes to deliver laser energy into the tumor, causing the tumor to shrink. ILT’s major advantages over the traditional lumpectomy are:

A micro-invasive surgical process – access via two small needles rather than a scalpel wound
Local anesthesia rather than general anesthesia or IV sedation
Minimal post-operative scar tissue
Reduced risk of surgical complications
Shorter preparation and quicker recovery time for patients
Does not preclude any future medical or surgical treatment options

“Thousands of women in the U.S. find breast tumors each year, and about 80 percent of all breast tumors are benign,” said Dr. Kambiz Dowlat, Professor of Surgery at Rush University Medical Center and founder of NOVIAN Health. “The traditional treatment for removing these tumors is a lumpectomy. Many women are hesitant to undergo this invasive surgery and, until now, that was really their only option. We believe that breast ILT provides women a better option to treat many tumors.”

NOVIAN Health Inc., located in Chicago, is a small, privately held company with proprietary technology for the treatment of tumors using Interstitial Laser Therapy (ILT). The company has developed, tested, and patented a micro-invasive surgical process that uses ILT (controlled heating) for the ablation of breast tumors as an alternative to the surgically invasive, traditional “lumpectomy.” ILT offers significant advantages over surgical removal including minimal scarring, quicker recovery times, and only requiring local anesthesia. NOVIAN Health recently received its first FDA 510k clearance and expects to offer its technology at centers around the country. Their plan is to launch several centers nationwide that will be associated with existing surgical practices.

Related Posts

  • Doctors Studying Less Invasive Alternative to Lumpectomy
  • Novilase Treatment for Benign Breast Tumors Featured at Breast Surgeons Meeting (04 May 2009)
  • Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors (2 Sept 2014)
  • Breast Tumor Laser
  • Novian Health Begins Breast Cancer Clinical Trial (12 April 2012)

Filed Under: Archives

Recent Posts

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

ARCHIVES

  • December 2022
  • September 2021
  • August 2021
  • July 2021
  • February 2021
  • September 2020
  • June 2020
  • September 2019
  • July 2019
  • June 2019
  • December 2015
  • December 2014
  • September 2014
  • May 2014
  • December 2013
  • April 2013
  • February 2013
  • April 2012
  • October 2011
  • September 2011
  • July 2011
  • November 2010
  • December 2009
  • November 2009
  • October 2009
  • May 2009
  • June 2008
  • March 2008
  • October 2007
  • June 2007

Categories

  • Archives
  • Press Release 2011
  • Press Release 2012
  • Press Release 2013
  • Press Release 2014
  • Press Release 2015
  • Press Release 2019
  • Press Release 2020
  • Press Release 2021
  • Press Release 2022

CONTACT US

Novian Health Inc.
(Headquarters)
Novian Health Inc.
(Manufacturing)
222 W Merchandise Mart Plaza
Suite 1230
Chicago, Illinois 60654
1205 E State Avenue
Tonganoxie, KS 66086
Office: 312-266-7200 Office: 312-266-7200
Fax: 312-266-7202 Fax: 312-266-7202
Email: info@novianhealth.com Email: info@novianhealth.com

    

LATEST NEWS

  • Novian Health Earns New Product Innovation Award for Novilase Breast Therapy (6 December 2022)
  • Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy (28 September 2021)
  • Novian Health Inc. Announces the Second Close of Convertible Note Financing (23 August 2021)
  • Novian Health Inc. Announces the First Close of Convertible Note Financing (28 July 2021)
  • Novian Health to Present at the Cavendish Global Summit on February 25, 2021 (12 February 2021)

Copyright © 2023 Novian Health. All Rights Reserved. Powered by